Alnylam Pharmaceuticals Ownership | Who Owns Alnylam Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Alnylam Pharmaceuticals Ownership Summary


Alnylam Pharmaceuticals is owned by 99.04% institutional investors, 1.47% insiders. Fmr is the largest institutional shareholder, holding 12.93% of ALNY shares. Capital Group Growth Fnd of Amer Comp is the top mutual fund, with 7.81% of its assets in Alnylam Pharmaceuticals shares.

ALNY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAlnylam Pharmaceuticals99.04%1.47%-0.52%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr16.77M12.93%$7.65B
Capital world investors16.43M12.67%$7.49B
Vanguard group13.57M10.46%$6.19B
Blackrock funding, inc. /de9.90M7.64%$4.52B
Blackrock9.55M7.57%$2.32B
Capital research global investors7.22M5.57%$3.29B
Jpmorgan chase4.54M3.50%$2.07B
State street3.08M2.38%$1.41B
Baillie gifford2.79M2.15%$1.27T
Geode capital management2.50M1.93%$1.14B

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals1.39M90.64%$634.89M
Bellevue group446.52K4.23%$203.61M
Parkman healthcare partners87.69K4.17%$39.99M
Orbis allan gray1.95M3.82%$889.64M
Rosenblum silverman sutton s f inc /ca34.00K3.54%$15.50B
Orbimed advisors301.60K3.24%$137.53M
Eagle health investments lp23.69K2.84%$10.80M
Palo alto investors lp32.32K2.73%$14.74M
Artia global partners lp34.57K2.50%$15.76M
Quantessence capital15.87K2.29%$7.24M

Top Buyers

HolderShares% AssetsChange
Jpmorgan chase4.54M0.12%2.48M
Norges bank2.46M0.08%2.46M
Arrowstreet capital, limited partnership1.36M0.39%1.19M
Fmr16.77M0.40%961.10K
Jane street group958.75K0.07%935.89K

Top Sellers

HolderShares% AssetsChange
Regeneron pharmaceuticals1.39M90.64%-3.05M
T. rowe price investment management2.17M0.61%-2.11M
Price t rowe associates inc /md/1.80M0.09%-1.34M
Winslow capital management1.33K0.00%-1.18M
Dodge & cox2.32M0.57%-875.87K

New Positions

HolderShares% AssetsChangeValue
Norges bank2.46M0.08%2.46M$577.94M
Massachusetts financial services co /ma/356.53K0.05%356.53K$162.58M
Susquehanna advisors group286.10K2.00%286.10K$130.46M
Congress asset management co /ma118.80K0.36%118.80K$54.17M
Bank of america corp /de/83.50K0.00%83.50K$20.29M

Sold Out

HolderChange
Bear mountain capital-1.00
Kohmann bosshard financial services-1.00
Salem investment counselors-1.00
Financial gravity asset management-1.00
Harbor investment advisory-1.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202582219.83%128,435,377-3.80%990.93%48136.26%215-3.15%
Jun 30, 20256852.09%133,478,5513.70%1021.04%3541.14%22010.00%
Mar 31, 202528-95.52%1,770,848-98.63%10.01%11-96.63%10-94.71%
Dec 31, 2024603-0.33%129,230,8605.02%1001.10%315-2.78%1836.40%
Sep 30, 20245994.17%123,006,4572.58%951.07%32010.73%1704.94%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Capital Group Growth Fnd of Amer Comp10.18M7.81%-
American Funds Growth Fund of Amer A10.18M7.81%-
Vanguard US Total Market Shares ETF4.07M3.15%54.28K
Vanguard Total Stock Mkt Idx Inv4.10M3.13%-95.47K
VA CollegeAmerica Amcap 529A3.73M2.89%658.62K
Capital Group New Perspective Comp2.93M2.25%-
American Funds New Perspective A2.93M2.25%-
Vanguard Mid Cap Index Institutional2.91M2.22%31.33K
Capital Group AMCAP Composite2.40M1.84%-
American Funds AMCAP A2.40M1.84%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 17, 2025Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$58.24K
Nov 17, 2025Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$167.53K
Nov 17, 2025Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$3.67M
Nov 17, 2025Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$43.21K
Nov 17, 2025Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$166.07K

Insider Transactions Trends


DateBuySell
2025 Q4-96
2025 Q3-80
2025 Q2-17
2025 Q1-152
2024 Q4-36

ALNY Ownership FAQ


Who Owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals shareholders are primarily institutional investors at 99.04%, followed by 1.47% insiders and -0.51% retail investors. The average institutional ownership in Alnylam Pharmaceuticals's industry, Biotech Stocks , is 45.24%, which Alnylam Pharmaceuticals exceeds.

Who owns the most shares of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s largest shareholders are Fmr (16.77M shares, 12.93%), Capital world investors (16.43M shares, 12.67%), and Vanguard group (13.57M shares, 10.46%). Together, they hold 36.06% of Alnylam Pharmaceuticals’s total shares outstanding.

Does Blackrock own Alnylam Pharmaceuticals?

Yes, BlackRock owns 7.57% of Alnylam Pharmaceuticals, totaling 9.55M shares as of Jun 2024. This represents 0.05% of BlackRock's total assets, with a market value of 2.32B$. In the last quarter, BlackRock increased its holdings by 522.66K shares, a 5.79% change.

Who is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 90.64% of its assets in 1.39M Alnylam Pharmaceuticals shares, valued at 634.89M$.

Who is the top mutual fund holder of Alnylam Pharmaceuticals shares?

Capital Group Growth Fnd of Amer Comp is the top mutual fund holder of Alnylam Pharmaceuticals shares, with 7.81% of its total shares outstanding invested in 10.18M Alnylam Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools